

**Fellow Publications/Presentations
January through December 2017**

Publications

1. Santa-Maria CA, **Kruse M**, Raska P, Weiss M, Swoboda A, Mutonga MB, Abraham J, Jain S, Nanda R, Montero AJ. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers. *Breast cancer research and treatment*. 2017; 166 (1) : 179-184. PMID: 28752189
2. **Greenberg E**, Vatolin S. Symbiotic Origin of Aging. *Rejuvenation Research*. 2017 Sep 25; doi: 10.1089/rej.2017.1973 [Epub ahead of print]. PMID: 28791889.
3. Barata PC, **Koshkin VS**, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. *Ann Oncol*. 2017 Oct; 28(10): 2458-2463. PMID: 28945843
4. Grivas P, **Koshkin VS**, Pal S. Cancer vaccines in the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? *Ann Oncol*. 2017 Apr; 28(4): 680-682. PMID: 28328001
5. Mendiratta P, Rini BI, **Ornstein MC**. Emerging immunotherapy in advanced renal cell carcinoma. *Urologic oncology*. 2017; 35 (12) : 687-693. PMID: 28889919
6. Barata PC, **Ornstein MC**, Garcia JA. The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. *Journal of kidney cancer and VHL*. 2017; 4 (2) : 10-18. PMID: 28725539
7. **Patel B.**, Przychodzen, Thota S, et. al. Genomic detrimants of chronic myelomonocytic leukemia. *Leukemia*. 2017 May 30; doi: 10.1038/leu.2017.164. [Epub ahead of print]. PMID 28555081
8. Hirsch CM, Przychodzen BP, Radivoyevitch T, **Patel B**, Thota S, Clemente MJ, Nagata Y, LaFramboise T, Carraway HE, Nazha A, Sekeres MA, Makishima H, Maciejewski JP. Molecular features of early onset adult myelodysplastic syndrome. *Haematologica*. 2017; 102 (6) : 1028-1034. PMID: 28255022
9. **Patel SS**, Sekeres M, Nazha A. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. *Leuk Lymphoma*. 2017 Nov;58 (11):2532-2539. doi: 10. 1080/10428194.2017.137361. Epub 2017 Mar 28. PMID 28351181
10. **Patel SS**, Gerds AT. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times. *Curr Hematol Malig Rep*. 2017 Oct;12(5):455-460. doi: 10.1007/s11899-017-0406-x.
11. Chaddha U, **Patil PD**, English R, Panchabhai TS. An Unusual Presentation of Cervical Carcinoma Metastasis as Mediastinal Adenopathy. *J Bronchology Interv Pulmonol*. 2017 Oct;24(4):e61-e63. doi: 10.1097/LBR.0000000000000408. PMID: 28957900

12. Chaddha U, **Patil PD**, English R, Walia R, Panchabhai TS. The Imitation Game: A 55-Year-Old Man With a Lung and Adrenal Mass. *J Bronchology Interv Pulmonol*. 2017 Oct;24(4):e52-e54. doi: 10.1097/LBR.0000000000000397. No abstract available. PMID: 28957895
13. **Patil PD**, Cua YM, Farver C, Perez RL, Mehta AC, Panchabhai TS. A 54-Year-Old Man With Anasarca, Dyspnea, and Recurrent Bilateral Pleural Effusions. *Chest*. 2017 Aug;152(2):e39-e44. doi: 10.1016/j.chest.2017.03.018. PMID: 28797399
14. Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, et al. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. *J Clin Apher*. 2017 Nov 14. PMID: 29134688
15. Mukhopadhyay S, **Patil PD**, Roma AA. Metastasis to the Lung From Carcinomas of Nonpulmonary Sites After Prolonged Disease-free Intervals. *J Bronchology Interv Pulmonol*. 2017 Jul;24(3):216-224. doi: 10.1097/LBR.0000000000000382. PMID: 28248821
16. Balasubramanian SK, Sadaps M, **Thota S**, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP. Rational management approach to pure red cell aplasia. *Haematologica*. 2017, Dec 7. PMID: 29217782
17. **Thota S**, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. *European journal of haematology*. 2017; 98 (5) : 425-434. PMID: 28152223
18. **Thota S**, Gerds AT. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. *Leukemia & lymphoma*. 201703; 75 : 1-10. PMID: 28771058
19. **Thota S**, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. *British journal of haematology*. 2017, Sep 14. PMID: 28905372
20. **Madanat YF**, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. *Clin Lymphoma Myeloma Leuk*. 2017 Dec;17(12):857-862. Epub 2017 Jul 14. PMID: 28778620
21. **Madanat YF**, Sekeres MA. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. *Semin Hematol*. 2017 Jul;54(3):147-153. Epub 2017 Jun 23. PMID: 28958288
22. **Khouri J**, Majhail NS. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma. *Curr Opin Support Palliat Care*. 2017 Dec;11(4):361-5. PMID: 28922292
23. **Zahoor H**, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. *Clinical genitourinary cancer*. 201717; 17 : 30311-7. PMID: 29154041

Poster Presentations/Abstracts

1. **Chakraborty R.** Impact of duration of Induction Therapy on Progression-Free Survival in patients with Newly Diagnosed Multiple Myeloma undergoing Upfront Autologous Stem Cell Transplantation. ASH Annual Meeting. December 2017 (Poster)
2. **Greenberg E** Hirsch C, Pan F, et. al. TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies. ASH Annual Meeting. December 2017 (Poster)
3. **Greenberg E**, Hirsch C, Chen S, et. al. Modulation of TET2 Activity with Ascorbic Acid in Myeloid Neoplasia: Diagnostic and Therapeutic Implications. ASH Annual Meeting. December 2017 (Poster)
4. **Khoury J**, Bicky T, Reu F, et. al. Daratumumab Is Safe and Highly Effective in AL Amyloidosis. ASH Annual Meeting. December 2017 (Poster)
5. **Khoury J**, Adema V, Ni Y, et. al. Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying *SF3B1* Hotspot Mutations. ASH Annual Meeting. December 2017 (Poster)
6. **Koshkin V**, Barata P, Zhang T, et. al. Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma. Kidney Cancer Symposium. November 2017 (**Oral**)
7. **Koshkin V.** Cisplatin-Based Neoadjuvant Chemotherapy (NAC) in Bladder Cancer Patients (Pts) with Borderline Renal Function: Implications for Clinical Practice. GU ASCO. February 2017 (Poster)
8. **Koshkin V.** Prognostic Value of DLL3 Expression and Clinicopathologic Features in Small Cell Bladder Cancer (SCBC). GU ASCO. February 2017 (Poster)
9. **Koshkin V.** Molecular Profiling of Small Cell Bladder Cancer (SCBC) Reveals Gene Expression Determinants of an Aggressive Phenotype. ASCO Annual Meeting. June 2017 (Poster)
10. **Koshkin V.** Nivolumab Treatment for Patients with Non-Clear Cell Renal Cell Carcinoma, a Multicenter Retrospective Analysis. ASCO Annual Meeting. June 2017 (Poster)
11. **Koshkin VS**, Hahn N, Grivas P. Phase Ib feasibility trial of neoadjuvant nivolumab/lirilumab in cisplatin-ineligible muscle-invasive bladder cancer. Presentation at Fall 2017 ECOG-ACRIN Cancer Research Group Meeting; Orlando, FL. October 2017. (**Oral**)
12. **Koshkin VS** and Grivas P. Integrative Molecular Profiling of Small Cell Bladder Cancer. BCCN Bladder Cancer Think Tank, John Quale Travel Fellow Lecture. August 2017 (**Oral**)
13. **Kunapareddy G**, Hooley J, Varella L, et. al. Implementation of an Interdisciplinary Care Team to Create Individualized Care Plans for High Risk Oncology Patients; A Model to Decrease Aggressiveness of Care at the End of Life and Improve Cost Effectiveness of Care. ASCO Palliative and Supportive Care in Oncology Meeting. October 2017 (Poster)

14. **Kunapareddy G**, Switzer G, Madison C, et. al. Implementation of an Electronic Medical Record Tool for Early Detection of Deep Vein Thrombosis in the Ambulatory Oncology Setting: The Cleveland Clinic Experience. ASH Annual Meeting. December 2017 (Poster)
15. **Kunapareddy G**, Hiner A, Patel S, et. al. Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies. ASH Annual Meeting. December 2017 (**Oral**)
16. **Kunapareddy G**, Hooley J, Pinnamaneni P, et. al. Creation of Individualized Care Plans in High Risk Oncology Patients: A Team Based Model to Decrease Unnecessary Hospitalizations and ED Utilization. ASH Annual Meeting. December 2017 (**Oral**)
17. **Madanat YF**, Sekeres M, Al-Issa K, et. al. Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS). ASH Annual Meeting. December 2017 (Poster)
18. **Madanat YF**, Radivoyevitch T, Nazha A, et. al. Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndrome (MDS). ASH Annual Meeting. December 2017 (**Oral**)
19. Al-Issa K, **Madanat YF**, Mukherjee S, et al. Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS). ASH Annual Meeting. December 2017 (Poster)
20. **Ornstein MC**. Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting. June 2017 (Poster)
21. **Patel B**. Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation. ASH Annual Meeting. December 2017 (Poster)
22. **Patel S**. Influence of MHC Class I Chain-Related Gene A (MICA) Polymorphisms on Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation. ASH Annual Meeting. December 2017 (**Oral**)
23. **Patel S**. Incidence, Treatment Patterns, and Outcomes of Histiocytic Disorders in the United States: A Forty-Year Population Study. ASH Annual Meeting. December 2017 (Poster)
24. **Sawalha Y**, Radivoyevitch T, Tulio K, et. al. The Role of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Population Based Study Using the National Cancer Data Base (NCDB). ASH Annual Meeting. December 2017 (Poster)
25. **Sawalha Y**, Elson P, Madanat Y, et. al. Characteristics, Mutational Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease. ASH Annual Meeting. December 2017 (Poster)
26. **Vulchi M**. Correlation of breast cancer index (BCI) results to lymphovascular invasion in early stage HR+ breast cancer. San Antonio Breast Conference. December 2017 (Poster)
27. **Zahoor H**. T cell infiltration in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC). GU ASCO. February 2017 (Poster)

28. **Zahoor H.** T cell infiltration in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC). ASCO Annual Meeting. June 2017 (Poster)